Roopa Industries Ltd

A sustained decline has pushed Roopa Industries Ltd to a fresh 52-week low of Rs 38.1 on 30 Mar 2026, marking a 20.89% drop over the past year that significantly outpaces the broader Sensex's 6.53% decline.

Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has declined to a fresh 52-week low of Rs.39.35 as of 18 Mar 2026. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures on its valuation and financial metrics.

Roopa Industries Ltd’s stock declined sharply to a new 52-week low of Rs.40.01 on 10 Mar 2026, marking a significant milestone in its recent price trajectory. This drop comes despite an initial gap-up opening and follows a brief two-day rally, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 July 2025, reflecting a change from the previous 'Sell' grade. However, the analysis and financial metrics discussed below are based on the company’s current position as of 18 February 2026, providing investors with the latest insights into the stock’s performance and outlook.

Roopa Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive price level. Despite recent share price declines and a challenging sector backdrop, the company’s improved price-to-earnings and price-to-book ratios relative to peers suggest a compelling entry point for investors willing to navigate near-term volatility.

Roopa Industries Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 07 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Roopa Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from very attractive to attractive territory. Despite a recent upgrade in valuation grades, the company’s overall market performance remains mixed, with significant divergence from benchmark indices such as the Sensex. This article analyses the evolving price attractiveness of Roopa Industries, comparing its key valuation metrics against historical averages and peer companies to provide a comprehensive investment perspective.

Roopa Industries Ltd’s shares touched a fresh 52-week low of Rs.41 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial health and valuation metrics.

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a fresh 52-week low of Rs 41.34, marking a significant decline amid a three-day losing streak that has seen the stock shed nearly 11% of its value. This downturn contrasts sharply with broader market trends and highlights ongoing pressures on the company’s share price.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness. The stock has experienced a notable downward trajectory over recent sessions, reflecting ongoing pressures within the company’s financial and market performance.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness and sector underperformance.

Roopa Industries has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a combination of subdued fundamental strength and bearish market signals, contributing to a cautious stance among investors.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.42, reflecting a significant decline amid a day marked by high volatility and underperformance relative to its sector peers.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.43 today, marking a significant price level amid a day of high volatility and mixed intraday movements.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, reported a challenging financial quarter ending September 2025, with declines in key metrics such as operating cash flow and return on capital employed. Despite significant long-term growth, recent performance issues underscore the need for operational improvements.